Our mission is to improve the lives of people impacted by cancer through the development of transformative oncolytic immunotherapies.

Theolytics is developing best-in-class oncolytic immunotherapies. We have pioneered a new approach to develop efficacious, targeted therapeutic candidates suitable for direct and intravenous (IV) delivery.

Our Pipeline

THEO-260

Our lead candidate is a novel oncolytic immunotherapy specifically evolved to target stromal rich tumours. It has three critical modes of action which together enable it to tackle the complex, immune-suppressed nature of advanced solid tumours.

Our Platform

Harnessing biology to discover and develop cancer therapeutics that are tested and selected from actual patient tumors from numerous patients. We leverage Darwinian natural selection to identify candidates that possess the attributes required for success in the treatment of patients.

Clinical Trials

We are a clinical-stage company with ongoing trials in Ovarian Cancer in Europe

(OCTOPOD-IV) and The United States of America (OCTOPOD-IP).

Pipeline

Our pipeline candidates have been rigorously selected using actual patient tumors and have the potential to make an impact in difficult-to-treat solid tumours where there remains significant unmet need.